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Background: Measurement of myocardial iron is key to the clinical management of patients at risk 
of siderotic cardiomyopathy. The cardiovascular magnetic resonance (CMR) relaxation parameter 
R2* (assessed clinically via its reciprocal T2*) measured in the ventricular septum is used to assess 
cardiac iron, but iron calibration and distribution data in humans is limited. 
Methods and Results: Twelve human hearts were studied from transfusion dependent patients 
following either death (heart failure n=7, stroke n=1) or transplantation for end-stage heart failure 
(n=4). After CMR R2* measurement, tissue iron concentration was measured in multiple samples 
of each heart using inductively coupled plasma atomic emission spectroscopy. Iron distribution 
throughout the heart showed no systematic variation between segments, but epicardial iron 
concentration was higher than in the endocardium. The mean (±SD) global myocardial iron causing 
severe heart failure in 10 patients was 5.98 ±2.42mg/g dw (range 3.19-9.50), but in 1 outlier case of 
heart failure was 25.9mg/g dw. Myocardial ln[R2*] was strongly linearly correlated with ln[Fe] 
(R2=0.910, p<0.001) leading to [Fe]=45.0•(T2*)-1.22 for the  clinical calibration equation with [Fe] in 
mg/g dw and T2* in ms. Mid-ventricular septal iron concentration and R2* were both highly 
representative of mean global myocardial iron.  
Conclusions: These data detail the iron distribution throughout the heart in iron overload and 
provide calibration in humans for CMR R2* against myocardial iron concentration. The iron values 
are of considerable interest with regard to the level of cardiac iron associated with iron-related death 
and indicate that the heart is more sensitive to iron loading than the liver. The results also validate 
the current clinical practice of monitoring cardiac iron in-vivo by CMR of the mid septum. 
 
Key Words: Magnetic resonance imaging, heart, iron overload, siderosis, thalassemia. 
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INTRODUCTION 
 
Transfusion-dependent patients receive approximately 20 times the normal intake of iron which 
leads to iron accumulation and damage in the liver, heart and endocrine organs.1,2 Although 
improvements in survival have been achieved over the last 40 years, iron induced cardiotoxicity 
remains a leading cause of morbidity and mortality, especially for patients with beta thalassemia 
major (TM),3,4,5,6 and once heart failure develops, the prognosis is poor.7 Therefore, assessment of 
myocardial iron is essential clinically but conventional non-invasive techniques are less than ideal. 
Neither serum ferritin nor liver iron concentration gives a reliable indication of cardiac iron in 
cross-sectional studies.8 Monitoring ejection fraction can be useful, but its value is limited by 
difficulty of reproducible longitudinal measurements, the masking of ventricular dysfunction by the 
basal high cardiac output seen in chronic anemia, and its late occurrence in the disease process. 
Even more modern contractile measures such as tissue Doppler imaging correlate poorly with 
cardiac iron.9 Endomyocardial biopsy is also unreliable for measuring myocardial iron due to 
sampling error with very small biopsy samples.10,11 The need for an alternative non-invasive 
measurement of myocardial iron led to the development of an optimized cardiac T2* magnetic 
resonance (MR) technique. Particulate intracellular iron causes shortening of the magnetic 
resonance relaxation parameter T2* (and hence increase in its reciprocal, R2*) due to microscopic 
magnetic field inhomogeneity. Myocardial T2* is an easily quantifiable, clinically robust and highly 
reproducible measurement technique.12,13,14 In the liver, T2* correlates well with biopsy iron 
concentration.8,15 Although the relationship between T2* and cardiac iron can be inferred from first 
principles, animal models,16 and the liver data, there is limited direct information on cardiac 
calibration of T2* in humans,17,18 and the inherent limitations associated with endomyocardial 
biopsy prevent in vivo calibration.19 We therefore initiated a project to calibrate cardiac T2* against 
chemically assayed tissue iron concentration in ex-vivo human hearts and determine its cardiac 
distribution.  
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METHODS 
 
Patient characteristics 
This project started in 2003 and was completed in 2010, during which time 12 whole human hearts 
were donated from five international centres: University College Hospital (London, UK), Ospedale 
Galleria (Genoa, Italy), Children’s Hospital of Los Angeles (USA), Azienda Ospedaliera Brotzu 
(Cagliari, Italy) and Mahidol University (Bangkok, Thailand). All patients were transfusion-
dependent (10 beta-thalassemia major, 1 sideroblastic anemia, 1 Diamond Blackfan anemia), most 
having required transfusions from early childhood. The hearts were donated following death or 
cardiac transplantation for end-stage heart failure. The study protocol was approved by all local 
research ethics committees, and local consent was obtained in all cases.  
 
Imaging protocol and analysis 
We used scientific convention in quoting R2* to evaluate relaxation and its relation to iron, R2* 
being the reciprocal of T2*. Scans performed on patients pre-mortem are quoted as T2*. All hearts 
were fixed in formalin. Each heart was cut into 4-5 slices of 1cm thickness in the ventricular short 
axis according to ventricular size (figure 1a,b). The apical cap was not analyzed for R2* because of 
potential for partial volume effects. All slices were imaged using a 1.5 Tesla MR scanner (Sonata, 
Siemens Medical Systems, Germany) with a 4-element phased-array coil. Slices were immersed in 
water in a custom-made container between two sheets of plexiglass and maintained at 37ºC 
throughout imaging (figure 1c). A multi-echo gradient echo sequence was used for imaging, and in 
order to cover R2* values from 25 to 500s-1 (T2* from 2 to 40ms), 2 sequences were required. For 
all hearts, a high resolution sequence with 16 echoes was used with TEs from 3.1 to 39.1ms. Slice 
thickness was 5mm, flip angle 35°, matrix 128x128 pixels, field of view 160mm, number of 
excitations 2 and sampling bandwidth 815Hz per pixel. An additional lower resolution sequence 
with a lower minimum TE was also performed with 12 echoes ranging from 1.21 to 14.9ms. For 
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this sequence, flip angle was 20°, matrix 64x64 pixels and sampling bandwidth 1955Hz per pixel. 
All other parameters were identical. The 2 sequences were compared in 6 ex-vivo hearts with a 
range of R2* from 125 to 278s-1 (T2* from 3.6 to 8.0ms), and found to agree closely with a 
coefficient of variation of 5.1%. Care was taken to orientate each slice, including photography, to 
ensure reliable identification of anatomy and wall segmentation for co-localization of R2* and 
chemically assayed iron concentration.  
 
For the measurement of R2*, each slice was analyzed with 18 regions of interest (ROIs) of 6 radial 
sectors of 60° each, and 3 layers: outer (epicardial), inner (endocardial) and intermediate 
(mesocardial) (figure 1d). The attachment of the right ventricular (RV) wall to the left ventricle 
(LV) was used to define the septum.20 R2* was measured from each ROI using dedicated software 
(Thalassaemia Tools, Cardiovascular Imaging Solutions, London) using a truncation model to 
account for background noise, as has been previously validated (figure 2).21 Analysis of the 12 echo 
sequence was only required for heart 4, which was extremely heavily iron loaded (R2* 500s-1, T2* 
2.0ms). In all other cases, the 16 echo sequence was used for analysis. 
 
Quantification of myocardial iron 
After R2* CMR was completed, each short axis slice was cut into 6 sectors of 60° each, and then 
each sector was subdivided into 3 transmural layers (18 LV samples, figure 1e). For each short axis 
slice, 2 samples were also taken from the RV free wall (20 myocardial samples per slice). 
Additional samples were taken from the right (3) and left (3) atrium, the inter-atrial septum (1) and 
each of the valves (4). For the LV myocardial R2* calibration analysis, all LV samples were 
directly compared with the CMR R2* scan. For the segmental analysis of the distribution of 
myocardial iron, we used the American Heart Association/ American College of Cardiology 
(AHA/ACC) 16-segment model.20 Three myocardial slices from each heart were used for this 
analysis: the mid-ventricular, apical and basal slices, as per the model. Each segment comprised the 
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full transmural extent of myocardium. To match the apical slice to 4 segments as dictated in the 16 
segment model, the 2 apical-septal sectors were analyzed together, and the 2 apical-lateral sectors 
were analyzed together. The wet weight of each piece of tissue was recorded after discarding excess 
formalin. Samples were then freeze-dried and the dry weight (dw) was recorded immediately after 
removal from the lyophilizer. Following acid digestion, iron measurement was performed using 
inductively coupled plasma atomic emission spectroscopy (ICP-AES). The iron concentrations in 
samples of NIST human liver standard 4352 were used as quality controls for ICP-AES analysis.  
 
Effect of time in formalin fixation on R2* measurement and iron concentration 
As the fixed hearts had been stored for varied lengths of time, the effect of formalin on MR 
relaxation and iron loss over time was studied. One myocardial slice was analysed at repeated 
intervals up to a total of 566 days (12 scans in total). Myocardial tissue from an apical slice not 
included in the segmental analysis was used to assess whether there was any leaching of iron from 
the myocardium into formalin over time. This 7.35g sample was preserved in 280mL of 10% 
neutral buffered formalin (pH 7.0). At repeated intervals up to 600 days, small (1mL) aliquots of 
formalin were taken for analysis of the iron content of the solution. The initial iron concentration in 
this tissue sample was estimated from immediately adjacent areas of myocardium in the same apical 
slice. 
 
Pre and post-mortem scans 
Three of the patients had clinical T2* scans shortly before death on the same scanner (Sonata) as 
was used for the ex-vivo scanning. Imaged was performed with a single breath-hold 8-echo T2* 
sequence as previously described (range of echo times: 2.6-16.74ms, slice thickness 10mm, flip 
angle 20°, matrix 128x256 pixels, field of view 400mm, sampling bandwidth 815Hz per pixel).13 
The anatomical appearance of the slice (papillary muscle position, trabecular pattern and distance 
from apex) was used to achieve as precise a correlation as possible between pre- and post-mortem 
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scans, allowing direct comparison of T2* values. Two mid-ventricular short-axis slices were 
imaged, which gave 12 myocardial regions of interest for comparison (2 slices, 2 septal sectors, 3 
transmural layers).  
 
Statistics 
For each distribution analysis, 1 region of interest was defined as the reference region, and 
differences in tissue iron content throughout the heart against this region were assessed using 
mixed-model linear regression. The null hypothesis was that there was no difference in iron 
concentration between segments, layers or slices. For each analysis, the regions of interest were 
entered as fixed effects, so that differences between regions could be estimated. Patients were 
entered as random effects, since it was not of interest to test for differences between individual 
patients. To account for the repeated measurements from each heart, all samples from each 
individual heart were nested for analysis. R2* was compared with iron concentration using linear 
regression. The degree of heterogeneity of iron concentration and R2* for each heart was evaluated 
by calculating the coefficient of variation of iron concentration across all samples. All data were 
analysed using STATA version 10.1 (StataCorp, Texas, USA). Mixed model linear regression 
analysis was performed using the “xtmixed” command within STATA. The “regress” command 
was used when performing standard linear regression. A value of P <0.05 was used to define a 
significant difference. 
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RESULTS 
 
Patient characteristics 
Twelve hearts were donated, 8 following death and 4 from patients undergoing cardiac 
transplantation for end-stage heart failure. End-stage heart failure was the cause of death in 7 of the 
8 patients who died, but one patient died from an ischemic stroke at the age of 46 with a history of 
excellent compliance to chelation therapy and no cardiac complications (apart from a transient 
episode of atrial fibrillation aged 21). Table 1 summarises the clinical information for each patient. 
 
Pre and post-mortem scans 
Three patients underwent both pre- and post-mortem T2* scans. The mean time between CMR scan 
and death was 26 ±13.3 days (range 11-35). There was no significant difference in T2* between 
scans. Mean ±SD T2* pre-mortem was 4.89 ±1.30, 6.01 ±0.81 and 10.87 ±2.34ms versus 5.21 
±0.43ms (P=0.28), 5.94 ±0.90ms (P=0.84) and 9.20 ±2.22ms (P=0.21) post-mortem for pairwise 
comparison of the septal regions of interest in hearts 2, 10 and 11 respectively (figure 3a, b, c). 
 
Effect of time in formalin on R2* measurement 
For the single short axis slice which was scanned at repeated intervals, there was no significant 
change in R2* value, even after 18 months’ storage in formalin (figure 3d). Mean R2* for all 
sectors was 198.4 ±21.5s-1 at day 6 and 197.7 ±7.3s-1 at day 566 (P=0.93). 
 
Loss of iron from stored myocardial samples 
The iron content of the formalin solution in which a piece of myocardial tissue had been stored over 
a period of 600 days is shown in figure 3e. Average iron concentration of adjacent myocardial 
tissue was 1.21 mg/g wet weight, corresponding to a total of 8.91mg of iron in the 7.35g wet weight 
sample. The iron concentration of the solution increased rapidly over the first 30 days after formalin 
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fixation, with a further subsequent rise but thereafter stabilised to reach a plateau of approximately 
480μg/L after 300 days, equating to a loss of 135μg (approximately 1.5%) of the total iron from the 
myocardial tissue.  
 
Myocardial iron samples: overall summary 
The mean (± SD) weight of all samples in the iron analysis was 1001 ±620mg. Iron concentration in 
all samples ranged from 0.09 to 78.64mg/g dw. The myocardial iron concentration ranged from 
0.18 to 53.4mg/g dw. The mean (± SD) ratio of dry to wet iron concentration in the myocardium 
was 5.04 ±0.9 and was independent of iron concentration. One heart had exceptionally high levels 
of iron and in view of the possibility that this could bias the results, all further analysis is presented 
separately for this outlier heart. The coefficient of variation of iron for myocardial samples ranged 
from 9.2% to 26.6% per heart with a mean of 15.2% (table 1). 
 
Distribution of left ventricular iron 
With all hearts considered together (except the most heavily iron-loaded heart (number 4), a 
gradient of iron was found in the transmural layers of the LV myocardium with the greatest 
concentration in the epicardium, an intermediate level in the mesocardium (-1.1%, p=0.63), and the 
lowest level in the endocardium (-7.5%, p=0.001) (figure 4a and table 2). No statistically significant 
systematic variations in iron concentration were observed between the different AHA segments. In 
order to examine for variation in larger regions of the LV, an analysis was also performed of 
variation in iron concentration of whole walls of the LV (inferoseptal, anteroseptal, anterior, 
anterolateral, inferolateral, inferior) encompassing all segments from base to apex, which again 
showed no significant systematic variation of mean iron concentration. A further analysis 
comparing the whole basal, mid-ventricular and apical slices also failed to show any significant 
systematic variation in mean iron concentration. The most heavily iron-loaded heart (heart 4) had 
very high iron concentration in the epicardium (36.1mg/g dw) with an intermediate level in the 
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endocardium (-28.0%) and the lowest level in the mesocardium (-54.7%) (figure 4a and table 2). 
There was no systematic variation in mean iron concentration between the different LV segments or 
from base to apex. 
 
Septal iron compared with global cardiac iron 
Iron concentration measured in the mid-septal slice was highly representative of global iron (figure 
4b).  Regression analysis showed a slope indistinguishable from 1 (1.06; 95% CI: 0.83 to 1.29) and 
an intercept indistinguishable from 0 (0.04; 95% CI: -1.57 to 1.66). The mean percentage (±SD) 
difference between mid-septal and global iron concentration was 10.5 ±13.4%. 
 
Distribution of iron in RV, atria and valves 
Excluding the most heavily iron-loaded heart (heart 4), all RV, atrial and valve samples showed 
lower iron levels compared to global LV iron (apart from the anterior left atrial wall where only a 
borderline difference was observed). The RV wall had up to 21.9% less iron (p<0.001). Compared 
to the mean global LV iron concentration, the left atrial iron concentration was up to 28.1% lower 
(p<0.001) and right atrial iron up to 57.0% lower (p<0.001). All 4 cardiac valves showed low iron 
concentrations which were up to 74.4% lower than the LV (p<0.001). Heart 4 showed a consistently 
higher level of iron in the atrial and valve samples but no difference between LV and RV iron (table 
3). 
 
Relation of R2* to tissue iron concentration 
Due to the very high level of iron in the most severely overloaded heart (heart 4), measurement of 
R2* might be underestimated. Therefore, the results of the MR relaxation calibration are presented 
twice, both including and then excluding this heart. A total of 1006 tissue samples and their 
corresponding ROIs were used for iron and R2* assessment, with 84 ROIs (8.3%) being excluded 
from the R2* analysis due to imaging artefact predominantly caused by cuts made at autopsy. A 
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curvilinear relation between R2* and cardiac iron concentration was observed (Figure 5a,b). A 
similar curvilinear relation was shown when mean global whole heart iron was plotted against R2* 
(figure 5c,d). The strongest linear correlation was found (all hearts) by plotting lnR2* and ln[Fe] 
(R2 0.910, p <0.001) with a slope of 0.745 [95% CI: 0.729–0.760] and intercept of 3.896 [95% CI: 
3.868–3.924] (figure 5e). There was almost no difference to this calibration result if heart 4 was 
excluded (R2 0.898, p <0.001, slope 0.754 [95% CI: 0.737–0.772], intercept 3.884 [95% CI: 3.855–
3.913]). Using this calibration in all hearts, the relation between R2* and iron is expressed by the 
formula (where myocardial [Fe] is measured in mg/g dw, and R2* is measured in s-1): 
 
[Fe]= 0.00985•(R2*)1.22 
 
R2* measured in the mid-septal slice was highly representative of whole-heart mean R2* (figure 
5f). Regression analysis showed a slope indistinguishable from 1 (0.97; 95% CI: 0.82 to 1.13) and 
an intercept indistinguishable from 0 (0.33; 95% CI: -0.73 to 1.38). The mean percentage (±SD) 
difference between mid-septal and global R2* was 2.8 ±7.3%. The relation of septal R2* and T2* 
with whole heart iron concentration is shown in figure 6.  
 
 
DISCUSSION 
 
This is the first report of a series of human hearts that have undergone both magnetic resonance 
relaxometry and quantitative iron studies for distribution and calibration purposes. The results of the 
distribution analysis show no systematic variation of iron concentration between all 16 myocardial 
segments, the 6 myocardial walls, or the 3 short axis slices from base to apex. However, 
systematically higher iron concentration was present in the epicardium. The mid-ventricular septal 
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iron concentration was highly representative of global iron concentration, and mid-ventricular R2* 
was highly representative of global R2*. 
 
Studies dating from the mid-1950s have assessed myocardial iron loading in post-mortem human 
hearts using various techniques including histological grading of iron-positive myocytes, electron 
microscopy and analysis of elemental iron by flameless atomic absorption 
spectroscopy.11,22,23,24,25,26,27 Our results are in broad agreement with the previously published 
studies which have observed a similar transmural gradient of myocardial iron. Two autopsy studies 
have attempted to quantify regional variation but no definite pattern has emerged,17,22 and this is the 
first time a comprehensive study of regional variation has been made.  
 
CMR studies have reported that some TM patients have a heterogeneous pattern of cardiac iron 
distribution, as measured by in vivo T2*, although this heterogeneity lessened with increasing iron 
concentration.28,29 Myocardial T2* in vivo may however be confounded by a number of factors, 
including magnetic susceptibility artefact as well as measurement error.30 In view of the problems 
with artefact in-vivo, it has been recommended that the measurement of T2* is restricted to a full 
thickness septal region of interest.8 There has been recent debate over the use of this septal ROI for 
predicting whole-heart iron,29 but our results validate this approach given that both iron and R2* 
measured in the mid-septum are highly representative of their respective global myocardial value.  
 
The results of the calibration analysis of myocardial MR relaxometry against absolute iron 
concentration are of considerable clinical interest. Heart R2* provided a robust (R2=0.910) 
calibration against chemically assayed cardiac iron in the current study. Our statistical analysis 
demonstrated that this relationship was curvilinear. Previous investigators have described a linear 
relationship between R2* and iron concentration, but these studies had fewer observations and a 
more limited range of measurement.17 Although R2* underestimation may occur at high iron 
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concentrations if initial echo times are too long, a minimum echo time of 1.2ms should have been 
adequate to capture even the most heavily loaded samples. In addition, we found little calibration 
differences if heart 4 was included or excluded. For clinical purposes, where T2* is typically the 
result quoted for patients with suspected cardiac iron overload, the calibration equation can be 
rewritten using T2* = 1000/R2* when the units of T2* are expressed in ms, and R2* in s-1: 
 
 [Fe]= 45.0•(T2*)-1.22 
 
Although direct comparison across species should be treated with caution, our results are 
comparable with R2* measurements in a gerbil model of severe iron loading where tissue iron 
concentration was measured from fresh, unfixed tissue.16 Proton relaxivity is known to be 
temperature dependent and in phantom studies, T2* falls by up to 1.5% per degree Celsius.31 We 
scanned all hearts at a constant 37°C and this may account for the consistency of our pre and post-
mortem heart measurements. The hearts in this study had been stored in formalin and there was a 
concern that this could affect the measurement of T2* and iron concentration. In agreement with 
previous work, we found only minor leaching of iron from myocardial tissue into the formalin 
solution and very little variation in the measured T2* over time.32  
 
The iron values obtained from our study are of considerable interest with regard to the level of 
cardiac iron concentration which is associated with iron-related death and cardiac disease, an issue 
that has hitherto been little explored. One previous study reported the normal myocardial iron 
concentration to be 0.34 (range 0.29-0.47) mg/g dw.33 The one heart we studied from a patient who 
died of a stroke with no evidence of heart disease and a normal myocardial T2*, had a global iron 
concentration of 0.38mg/g dw, which is in good agreement with the previous study. Of 10 hearts 
with similar ranges of myocardial siderosis, the mean global myocardial iron causing severe heart 
failure was 5.98 ±2.42mg/g dw (range 3.19-9.50), but in 1 outlier case of heart failure, myocardial 
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iron was 25.9mg/g dw. The values seen in the 10 hearts are rather modest in comparison with iron 
levels commonly seen in the liver in TM, and this indicates that the heart is considerably more 
sensitive to iron loading than the liver in terms of functional consequences. The outlier heart had 5 
times the iron concentration compared to the mean value of the other hearts, which was a totally 
unexpected finding. The explanation for this tolerance to myocardial iron can only be speculative, 
but may have been genetically mediated.  
 
Also of interest is the myocardial T2* value in relation to the development of heart failure and 
death. Previous ranges for T2* in vivo have been derived solely from clinical observations. In 
normal volunteers with no history of blood transfusion or iron overload, Anderson’s first paper on 
myocardial T2* found a mean normal value of 52ms,8 which yields a myocardial iron concentration 
of 0.36mg/g dw from our calibration. More recently, a normal mean value of 40ms has been widely 
used which equates to 0.50mg/g dw. These values accord well with the previous published normal 
values for myocardial iron,33 and also with the global myocardial T2* value (44.4ms) of one patient 
in our study who died of a stroke. The myocardial T2* values associated with being below the 
normal range are typically those below 20ms (1.1 mg/g dw), and as T2* falls below 10ms (2.7mg/g 
dw), there is a progressive decline in both LV and RV ejection fraction.8,34 The vast majority of 
patients who present with heart failure due to cardiac iron overload have T2* <10ms and low T2* 
values are powerful independent predictors of subsequent development of cardiac failure.35 All but 
one of the hearts in this study were from patients who had either died from or had undergone 
cardiac transplantation for end-stage heart failure. In keeping with clinical experience, the mean 
myocardial T2* was 5.9 ±3.0ms (range 2.0-12.3).  
 
Limitations 
This project has required international collaboration between specialist centres and could not have 
been performed with fresh, unfixed hearts due to regulations on transport of human tissue between 
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sites. The fact that death from cardiac failure is almost always restricted to patients with severe 
cardiac iron loading (T2* <10ms) is reflected in the range of T2* values. Although there is no 
guarantee that in-vivo and ex-vivo myocardial T2* are the same, the data are supportive with a 
good agreement between pre- and post-mortem T2* values in 3 hearts. Some hearts had been stored 
in formalin over extended periods, but our data suggest that there is no significant change in T2* 
over time and only a small amount of leaching of iron into the formalin solution. Although every 
effort was made to correlate ROIs used for R2* measurement with the tissue blocks that were 
analysed for iron concentration, it is not possible to eliminate disparity completely There are 
difficulties with R2* measurement in heavily iron-loaded tissue where signal decay is rapid, 
requiring very short echo times. Scanner hardware imposes constraints on minimum echo spacing 
which may be inadequate for accurate R2* measurement at very high iron concentrations. However, 
a minimum echo time of 1.2ms should allow reliable measurement of T2* values as low as 
1.44ms,16 which is below the minimum global myocardial value seen in this study. Finally, some 
ROIs were excluded from the calibration due to imaging artefact. The decision to exclude an ROI 
was made by subjective assessment prior to the analysis of R2* and is unlikely to have affected the 
calibration significantly due to the many regions sampled throughout the 12 hearts.  Previous 
reports have examined the myocardial relaxation parameter T2 in relation to cardiac iron in animal 
models,36 and in humans.16,19 T2 imaging can be challenging however, and it is not in routine 
clinical use, although recent imaging advances have been made.37 Due to the ease of acquisition and 
robust nature of T2* for clinical practice, we have concentrated on this technique. 
 
CONCLUSIONS 
 
The results of the current study validate the clinical technique in current use, and provide detailed 
calibration and distribution data in humans. 
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Figure Legends 
 
Figure 1. Experimental setup.  
A) Diagram of short-axis cardiac slices showing regions of interest (ROIs); B) Set of slices from a 
single heart; C) Slices inside scanner; D) Ex-vivo CMR image with ROIs used to determine T2* 
decay; E) Identical slice with segmentation performed to correspond with ROIs used for T2* 
measurement. 
 
Figure 2. Example of ex-vivo cardiac T2* scans. 
Representative images of two hearts are shown at increasing echo times (TE) from 3ms to 17.4ms. 
Heart 1 has normal iron levels and remains bright whereas heart 2 (which has severe iron loading) 
shows progressive darkening with increasing echo time. The graph shows signal intensity (arbitrary 
units) plotted against echo time (ms) for the hearts in upper panel. Heart 1 has a shallow decay 
curve with T2* value of >20ms. Heart 2 has a much more rapid decay with T2* <10ms. 
 
Figure 3. Pre and post-mortem scans. 
A) A pre-mortem mid-ventricular slice and B) the corresponding post-mortem slice of the same 
heart at the same position; C) Relationship between pre- and post-mortem T2* values measured 
from corresponding regions of interest in the mid-ventricular septum. Error bars represent standard 
deviation and the line of identity is given; D) R2* values measured from a single myocardial slice 
stored in formalin over a prolonged duration showing no significant change in R2*. The dashed line 
represents mean R2* (194.4s-1) and error bars are ±SD; E) Iron content of the formalin solution in 
which a piece of myocardial tissue was stored, showing an initial rapid increase in iron which 
reaches a plateau after the first 300 days. There is an early and a late plateau, possibly suggesting a 
two-stage process of iron release, however no further iron appears to be lost after the first 300 days. 
Note that T2* (decay constant in milliseconds) is in widespread use for clinical iron assessment and 
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is shown for the patient scan results, but that R2* (transverse relaxation rate in s-1) has been used to 
compare measurements in post-mortem hearts as it has a more linear relation to iron concentration. 
 
Figure 4. Myocardial iron distribution. 
A) Histogram showing transmural gradient across the LV myocardium; B) Graph of mid-septal iron 
concentration versus mean whole-heart iron concentration for each of the 12 hearts (data points are 
plotted against the line of identity, and error bars are ±SD of the septal samples). The double lines 
across each axis represent a discontinuity in the scale between 15 and 25mg/g for illustrative 
purposes. 
 
Figure 5. Calibration of CMR versus myocardial iron concentration. 
A) R2* plotted against myocardial iron concentration measured from each myocardial ROI. The 
regression (solid line) and 95% confidence bands (dotted lines) are shown and derived from 
analysis of the log-log data shown in figure 5E.; B) R2* versus myocardial iron concentration 
excluding heart 4. The regression (solid line) and 95% confidence bands (dotted lines) are shown 
and derived from analysis of the log-log data shown in figure 5E; C) Mean R2* plotted against 
mean iron concentration for each heart. The regression (solid line) is derived from analysis of the 
log-log data shown in figure 5E; D) Mean R2* versus mean iron concentration excluding heart 4. 
The regression (solid line) is derived from analysis of the log-log data shown in figure 5E; E) 
ln(R2*) plotted against ln([Fe]) for all ROIs, including heart 4 showing the best fit linear regression 
line; F) Mean mid-septal R2* versus mean whole-heart R2* plotted against the line of identity, 
showing that the septal R2* value is highly representative of the whole-heart R2* (only 11 hearts 
are shown because severe artefact prevented analysis of mid-septal T2* in one heart). 
 
Figure 6. Septal CMR measurements versus myocardial iron concentration. 
A) Mean septal R2* plotted against mean iron concentration for each heart. Error bars are ±SD for 
septal R2* and the regression line is shown based on the log-log data shown in figure 5E. B) Mean 
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septal T2* plotted against mean iron concentration for each heart. These two graphs illustrate the 
difference between T2* and R2* when compared to tissue iron. T2* shortens with increased iron 
concentration and hence its reciprocal R2* rises with tissue iron. T2* is used for clinical assessment 
of cardiac iron for historical reasons. 
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Table legends 
 
Table 1. Patient characteristics and clinical information. SD =standard deviation; LV =left 
ventricle; [Fe] =myocardial iron concentration; TM =Beta thalassemia major; SA =Sideroblastic 
anemia; DBA =Diamond Blackfan anemia; CoV =Coefficient of variation; N/A =not applicable 
(patients 3 and 4 did not receive iron chelation therapy: *died 1964; †died 1972). 
 
Table 2. Distribution of iron throughout the left ventricular myocardium. The differences in iron 
concentration (Δ) are compared against the mean global heart [Fe] dw, except for the transmural 
distribution where values are compared against the epicardium as the reference. AHA segments are 
numbered and labelled as: ant = anterior; sep = septum; lat = lateral; inf = inferior). Heart 4 is 
presented separately as it is an extreme outlier with very high myocardial iron concentration. 
 
Table 3. Distribution of iron in the right ventricle, atria and valves. The differences in iron 
concentration (Δ) are compared against the mean [Fe] dw for a reference region.
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Table 1. Patient characteristics and clinical information. SD =standard deviation; LV =left 
ventricle; [Fe] =myocardial iron concentration; TM =Beta thalassemia major; SA =Sideroblastic 
anemia; DBA =Diamond Blackfan anemia; CoV =Coefficient of variation; N/A =not applicable 
(patients 3 and 4 did not receive iron chelation therapy) #died 1964; †died 1972).  
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1 M TM Death 46 Ischemic stroke 
(no cardiac failure) 
0.38  
±0.13 
21.1 44.4  
±5.3 
1584 6 Excellent 
2 F SA Death 62 Cardiac failure 8.20  
±1.44 15.9 
4.7  
±0.6 
2000 42 Good 
3 M TM Death 10 Cardiac failure 9.50  
±1.88 9.2 
3.7  
±0.6 
170 N/A# N/A 
4 F TM Death 15 Cardiac failure 25.9  
±10.3 17.6 
2.0  
±0.4 
288 N/A† N/A 
5 F TM Death 20 Cardiac failure 7.74  
±1.51 16.4 
3.6  
±0.5 
432 6 Poor 
6 M TM Transplant 23 Cardiac failure 3.63  
±0.82 18.0 
8.0  
±1.0 
765 10 Not known 
7 M TM Transplant 24 Cardiac failure 3.38  
±0.53 10.0 
7.7  
±1.2 
528 6 Good 
8 M TM Transplant 21 Cardiac failure 5.87  
±1.0 9.5 
4.4  
±0.6 
500 4 Not known 
9 F TM Transplant 31 Cardiac failure 8.78  
±1.88 10.5 
3.9  
±0.6 
624 7 Poor 
10 M TM Death 24 
Cardiac failure & 
mucormycosis 
5.64  
±1.36 17.3 
5.8  
±1.4 
660 10 Poor 
11 M TM Death 44 Cardiac failure 3.19  
±1.02 26.6 
12.3  
±2.6 
1209 18 Poor 
12 M DBA Death 22 
Cardiac failure & 
pneumonia 
3.91  
±0.86 10.1 
8.8  
±1.8 
442 10 Poor 
 
Carpenter, T2* and cardiac iron 28 CIRCULATIONAHA/2010/007641 
 
  
Table 2.  Distribution of iron throughout the left ventricular myocardium. The differences in iron 
concentration (Δ) are compared against the mean [Fe] dw for a reference (ref) region. AHA 
segments are numbered and labelled as: ant = anterior; sep = septum; lat = lateral; inf = inferior). 
 All hearts (excluding heart 4)  Heart 4 alone 
LV Region of interest [Fe] mg/g 95% CI p value  [Fe] mg/g 95% CI p value 
Epicardium (reference) 6.17 4.65 7.69 Ref  36.10 31.58 40.62 Ref 
Mesocardium (∆) -0.07 -0.34 0.20 0.63  -19.75 -21.71 -17.79 <0.001 
Endocardium (∆) -0.46 -0.73 -0.19 0.001  -10.11 -12.75 -7.46 <0.001 
Global LV (reference) 6.01 4.30 7.72 Ref  26.15 23.31 28.99 Ref 
B
as
al
 
1 Ant (∆) -0.37 -1.30 0.56 0.43  1.12    
2 Ant-sep (∆) 0.09 -0.84 1.02 0.85  -7.31    
3 Inf-sep (∆) -0.27 -1.20 0.66 0.57  -6.59    
4 Inf (∆) -0.41 -1.34 0.52 0.39  5.26    
5 Inf-lat (∆) -0.14 -1.07 0.79 0.77  -4.09    
6 Ant-lat (∆) 0.38 -0.55 1.31 0.43  -2.99    
M
id
 
7 Ant (∆) 0.03 -0.90 0.96 0.94  4.39    
8 Ant-sep (∆) 0.50 -0.43 1.43 0.29  3.05    
9 Inf-sep (∆) 0.59 -0.34 1.52 0.22  -1.33    
10 Inf (∆) -0.01 -0.94 0.92 0.98  -0.67    
11 Inf-lat (∆) 0.02 -0.91 0.95 0.97  2.23    
12 Ant-lat (∆) 0.43 -0.50 1.36 0.37  1.06    
A
pi
ca
l 
13 Ant (∆) 0.08 -0.85 1.01 0.87  4.88    
14 Sep (∆) -0.29 -1.22 0.64 0.54  -4.43    
15 Inf (∆) -0.12 -1.05 0.81 0.81  8.57    
16 Lat (∆) -0.50 -1.43 0.43 0.29  3.69    
Global LV (reference) 5.99 4.28 7.71 Ref  26.15 23.31 28.99 Ref 
Anterior (∆) -0.07 -0.93 0.78 0.87  3.46 -5.30 12.23 0.39 
Anterolateral (∆) 0.16 -0.70 1.01 0.72  -0.36 -8.30 7.58 0.93 
Inferolateral (∆) -0.06 -0.91 0.80 0.89  1.56 -6.38 9.50 0.69 
Inferior (∆) -0.16 -1.02 0.69 0.71  4.39 -3.31 12.09 0.26 
Inferoseptal (∆) -0.06 -0.92 0.79 0.89  -3.93 -7.39 -0.48 0.28 
Anteroseptal (∆) 0.20 -0.66 1.05 0.65  -5.11 -8.29 -1.93 0.16 
Apical (∆) 0.27 -0.55 1.10 0.51  1.99 -4.41 8.40 0.49 
Mid (∆) -0.17 -1.00 0.66 0.69  0.44 -7.18 8.06 0.88 
Basal (∆) -0.11 -0.93 0.72 0.80  -2.43 -9.30 4.44 0.40 
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Table 3. Distribution of iron in the right ventricle, atria and valves. The differences in iron 
concentration (Δ) are compared against the mean LV [Fe] dw. 
 
  All hearts (excluding heart 4)  Heart 4 alone 
 Region of interest [Fe] mg/g 95% CI p value  [Fe] mg/g 95% CI p value 
R
ig
ht
 V
en
tr
ic
le
 
Global LV [Fe] (reference) 5.98 4.52 7.45 Ref  26.15 23.31 28.99 Ref 
RV Posterior (∆) -1.26 -1.75 -0.78 <0.001  2.55 -3.86 8.96 0.68 
RV Anterior (∆) -1.31 -1.80 -0.83 <0.001  10.50 5.51 15.50 0.10 
Global LV [Fe] (reference) 5.98 4.52 7.45 Ref  26.15 23.31 28.99 Ref 
Apical (∆) -0.98 -1.57 -0.39 0.001  6.73 6.59 6.95 0.38 
Mid (∆) -1.43 -2.02 -0.84 <0.001  7.16 -0.69 15.00 0.35 
Basal (∆) -1.45 -2.04 -0.86 <0.001  5.69 -10.07 21.45 0.46 
A
tr
ia
 a
nd
 v
al
ve
s 
Global LV [Fe] (reference) 5.98 4.57 7.39 Ref  26.15 23.31 28.99 Ref 
LA anterior (∆) -0.78 -1.64 0.09 0.080  45.92    
LA posterior (∆) -1.68 -2.59 -0.76 <0.001  13.26    
LA lateral (∆) -1.11 -1.98 -0.24 0.013  30.81    
Atrial septum (∆) -2.99 -3.86 -2.12 <0.001  20.81    
RA anterior (∆) -3.28 -4.15 -2.41 <0.001  34.22    
RA posterior (∆) -3.41 -4.28 -2.54 <0.001  22.17    
RA lateral (∆) -3.09 -3.95 -2.22 <0.001  23.39    
Aortic valve (∆) -4.45 -5.57 -3.33 <0.001  42.60    
Mitral valve (∆) -4.37 -5.23 -3.50 <0.001  52.49    
Pulmonary valve (∆) -4.33 -5.45 -3.21 <0.001  41.12    
Tricuspid valve (∆) -4.40 -5.26 -3.53 <0.001  52.35    
 
